TEL AVIV, Israel
May 24, 2013
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that
, the Company's President and Chief Executive Officer, and
, the Company's Chief Financial Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on
Thursday May 30, 2013
at The Pfister Hotel, 424 East Wisconsin Ave.,
The format of the conference includes a number of 1-on-1 meetings arranged by Benchmark, with investors. Investors interested in meeting with Mr. Milinazzo and Mr. Shore should contact a Benchmark representative to arrange a meeting.
The Company will discuss the global commercial plan for its MGuard
Embolic Protection Stent (EPS) platform, its U.S. FDA clinical trial program, and the six month follow-up results of its MASTER I trial, which were presented yesterday at EuroPCR 2013, held
at the Palais des Congrès in
About The Benchmark Company, LLC
New York City
, The Benchmark Company, LLC is an institutional brokerage firm with offices in 12 cities throughout
the United States
About Stenting and MGuard™ EPS
Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.
In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.
The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.